Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M161Revenue (TTM) $M63.4Net Margin (%)5.0Altman Z-Score15.5
Enterprise Value $M65.0EPS (TTM) $0.2Operating Margin %9.1Piotroski F-Score6
P/E(ttm)56.6Beneish M-Score1.1Pre-tax Margin (%)6.2Higher ROA y-yY
Price/Book1.410-y EBITDA Growth Rate %--Quick Ratio14.2Cash flow > EarningsN
Price/Sales2.75-y EBITDA Growth Rate %--Current Ratio15.7Lower Leverage y-yY
Price/Free Cash Flow159y-y EBITDA Growth Rate %--ROA % (ttm)2.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)2.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M13.6ROIC % (ttm)21.7Gross Margin Increase y-yY

Gurus Latest Trades with GENC

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
GENCKeeley Asset Management Corp 2010-03-31 Sold Out $4.6 - $5.2
$ 11.89144%Sold Out0
GENCKeeley Asset Management Corp 2009-09-30 Buy $4.25 - $5.73
$ 11.89146%New holding45,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GENC is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

GENC: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Mellen Eric ECFO 2016-08-17Buy10,000$10.7510.6view
Houtkin Sherry10% Owner 2016-07-27Sell7,077$11.94-0.42view
Houtkin Sherry10% Owner 2016-07-26Sell10,500$11.543.03view
Houtkin Sherry10% Owner 2016-07-22Sell3,000$11.255.69view
Houtkin Sherry10% Owner 2016-07-21Sell15,000$11.235.88view
Houtkin Sherry10% Owner 2016-07-19Sell9,000$11.255.69view
Houtkin Sherry10% Owner 2016-07-15Sell20,312$11.166.54view
Houtkin Sherry10% Owner 2016-07-13Sell22,500$10.6711.43view
Houtkin Sherry10% Owner 2016-07-11Sell15,377$10.1716.91view
Houtkin Sherry10% Owner 2016-07-07Sell17,835$10.0518.31view

Quarterly/Annual Reports about GENC:

News about GENC:

Articles On GuruFocus.com
Mario Gabelli Gives Stock Recommendations Feb 26 2016 
Winning with the Net Current Asset Value Approach to Stocks Sep 04 2013 
Ben Graham Net-Net Newsletter: TSR (TSRI) One Year Later Apr 09 2012 
“Assign Yourself the Right Story” Mar 05 2012 
Ben Graham Net-Net Newsletter: Gencor (GENC) One Year Later Feb 29 2012 
How Long Should You Hold a Net-Net? Feb 13 2012 
Opt-Sciences $OPST- Follow Up Feb 01 2012 
Four Stocks to Fit in a Basket of Negative Enterprise Value with Certain Profitability Dec 23 2011 
Gencor ($GENC)- A free business with a huge portfolio Dec 22 2011 
Genco Industries: $15 Million in Cash and the Company for Free Sep 28 2011 

More From Other Websites
Data from Phase III CASTOR Study of Daratumumab Published in The New England Journal of Medicine Aug 24 2016
Genmab Announces European Regulatory Submission for Daratumumab in Relapsed Multiple Myeloma Aug 23 2016
Articles of Association for Genmab A/S Aug 18 2016
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their... Aug 18 2016
Graphics Chip Titan Registers Insider Selling; Four Other Companies with Fresh Insider Buying Aug 18 2016
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in... Aug 17 2016
GENCOR INDUSTRIES INC Financials Aug 17 2016
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their... Aug 17 2016
Capital Increase in Genmab as a Result of Employee Warrant Exercise Aug 17 2016
ETF’s with exposure to Gencor Industries, Inc. : August 16, 2016 Aug 16 2016
Gencor Industries, Inc. :GENC-US: Earnings Analysis: Q3, 2016 By the Numbers : August 12, 2016 Aug 12 2016
Genmab Enters Commercial License Agreement with Gilead for DuoBody® Technology Aug 10 2016
Genmab Announces Financial Results for the First Half of 2016 and Improves 2016 Financial Guidance Aug 09 2016
Gencor posts 3Q profit Aug 09 2016
Gencor posts 3Q profit Aug 09 2016
GENCOR INDUSTRIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 09 2016
Gencor Releases Third Quarter Fiscal 2016 Results Aug 09 2016
Genmab Appoints Board Observer Aug 03 2016
Daratumumab Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration in... Jul 25 2016
ETF’s with exposure to Gencor Industries, Inc. : July 18, 2016 Jul 18 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)